Royal Bank of Canada reiterated their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research report report published on Wednesday, reports. Royal Bank of Canada currently has a C$23.00 price target on the specialty pharmaceutical company’s stock.

Separately, TD Securities raised their target price on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a hold rating in a research note on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of C$22.50.

Shares of Valeant Pharmaceuticals Intl (TSE VRX) opened at C$19.48 on Wednesday. Valeant Pharmaceuticals Intl has a 12 month low of C$11.20 and a 12 month high of C$25.38.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

In related news, Director Schutter Richard Urbain De purchased 4,900 shares of the business’s stock in a transaction on Monday, August 21st. The stock was acquired at an average price of C$14.35 per share, for a total transaction of C$70,315.00.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Stock Target Prices

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.